[91] found that recombinant human erythropoietin (rhEPO) could inhibit the activity of NF-κB and iNOS, reduce the expression of BUN, Cre, GOT, GPT, and CPK which are kidney injury markers after rhabdomyolysis, and relieve AKI induced by rhabdomyolysis in rats. Here, PIK3C2A is linked to rhabdomyolysis.